CDA

Cytidine deaminase · P32320 · CDA on Sugi Atlas →

7,465 patent compounds predicted against CDA, 4,573 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL172268	0.60	15/20
SCHEMBL2713063	0.60	15/20
SCHEMBL171923	0.67	13/20
Tetrahydrouridine (SCHEMBL127270)	0.66	13/20
Tetrahydrouridine (SCHEMBL171865)	0.66	13/20
Tetrahydrouridine (SCHEMBL172272)	0.66	13/20
Tetrahydrouridine (SCHEMBL587704)	0.66	13/20
SCHEMBL586883	1.00	12/20
SCHEMBL587511	1.00	12/20
Cedazuridine (SCHEMBL170217)	1.00	11/20
Cedazuridine (SCHEMBL172256)	1.00	11/20
SCHEMBL583301	1.00	11/20
SCHEMBL586993	1.00	11/20
SCHEMBL587033	1.00	11/20
SCHEMBL586972	0.54	11/20
SCHEMBL40762	0.66	10/20
SCHEMBL399314	0.66	10/20
SCHEMBL3114394	0.58	9/20
SCHEMBL3114401	0.58	9/20
SCHEMBL1964824	0.52	9/20

Clinical trials — most relevant to CDA by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Acelarin First Line Randomised Pancreatic Study	PHASE2/PHASE3	SUSPENDED
Gemcitabine Hydrochloride in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery	PHASE2	COMPLETED
Cladribine in Patients With Mantle Cell Lymphoma	PHASE2	COMPLETED
Gene Therapy ADA Deficiency	PHASE1/PHASE2	COMPLETED
Gene Therapy for Adenosine Deaminase Severe Combined Immune Deficiency Using Peripheral Blood and EFS ADA Vector	PHASE1/PHASE2	RECRUITING
Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma	PHASE1/PHASE2	COMPLETED
Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome	PHASE1/PHASE2	COMPLETED
Capecitabine as Second-Line Therapy in Treating Patients With Stage IV Pancreatic Cancer Who Have the Thymidylate Synthase Gene	PHASE2	COMPLETED
Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)	PHASE1/PHASE2	COMPLETED
Gene Therapy for ADA-SCID	PHASE1/PHASE2	COMPLETED
Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML)	PHASE2	COMPLETED
Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML	PHASE2	RECRUITING
A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)	PHASE2	COMPLETED
SGI-110 and Donor Lymphocyte Infusions (DLI) After Allogeneic Stem Cell Transplantation	PHASE2	UNKNOWN
Autologous CD34+ Hematopoietic Stem Cells Transduced ex Vivo With Elongation Factor 1 Alpha Shortened (EFS) Lentiviral Vector Encoding for the Human ADA Gene	PHASE1/PHASE2	COMPLETED
Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency	PHASE1	COMPLETED
Treatment of SCID Due to ADA Deficiency With Autologous Transplantation of Cord Blood or Hematopoietic CD 34+ Cells After Addition of a Normal Human ADA cDNA by the EFS-ADA Lentiviral Vector	PHASE1	COMPLETED
FdCyd and THU for Advanced Solid Tumors	PHASE1	COMPLETED
Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas	PHASE1	COMPLETED
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors	PHASE1	RECRUITING
5-Fluoro-2'-Deoxcyctidine and Tetrahydrouridine to Treat Patients With Advanced Cancer	PHASE1	COMPLETED
Evaluation of Adenosine Deaminase (ADA) Enzyme Deficiency in Patients With Lymphopenia and/or Elevated Immunoglobulin E	nan	UNKNOWN
Observational Study Evaluating the Prevalence of Enzyme Deficiency in Pulmonology Clinics (ADA)	nan	UNKNOWN
Prevalence of Adenosine Deaminase (ADA) Enzyme Deficiency Disease in Adult Patients With Pulmonary Alveolar Proteinosis	nan	UNKNOWN
Gene Therapy for ADA-SCID Using an Improved Lentiviral Vector (Ivlv-ADA)	nan	RECRUITING
An Observational LTFU Study for Patients Previously Treated With Autologous ex Vivo Gene Therapy for ADA-SCID	nan	ENROLLING_BY_INVITATION
Role of ADA SNPs in Subjects With Relapsing Multiple Sclerosis (RMS)	nan	UNKNOWN
Clinical Genetics Branch Eligibility Screening Survey	nan	NOT_YET_RECRUITING
Pilot Evaluation of a Microfluidic Assay to Detect Minimal Residual Disease and Predict Relapse in AML Patients	nan	COMPLETED
Phase I/II Clinical Trial Stem Cell Gene Therapy in RAG1-Deficient SCID	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a CDA binder may also engage these)

Protein	Name	Similarity
P56389	—	0.988	P56389 →
Q4V7V8	—	0.958	Q4V7V8 →
Q0P4H0	—	0.946	Q0P4H0 →
Q5XIG6	—	0.937	Q5XIG6 →
O95671	—	0.936	O95671 →
Q5RFI8	—	0.936	Q5RFI8 →
P33571	—	0.936	P33571 →
P13439	—	0.935	P13439 →
Q5R514	—	0.934	Q5R514 →
Q5RIV4	—	0.934	Q5RIV4 →
GLS2	Glutaminase liver isoform, mitochondrial	0.934	landscape →
Q7TSV4	—	0.934	Q7TSV4 →
Q68FH4	—	0.933	Q68FH4 →
Q4R3Y4	—	0.933	Q4R3Y4 →
A0A1F3	—	0.932	A0A1F3 →
Q14CH1	—	0.931	Q14CH1 →
LDHA	L-lactate dehydrogenase A chain	0.931	landscape →
Q5R824	—	0.931	Q5R824 →
Q0V9A9	—	0.931	Q0V9A9 →
Q9XT87	—	0.931	Q9XT87 →
Q6P1M0	—	0.931	Q6P1M0 →
Q96NN9	—	0.931	Q96NN9 →
P19356	—	0.930	P19356 →
Q501L1	—	0.930	Q501L1 →
B4G0F3	—	0.930	B4G0F3 →
P00341	—	0.930	P00341 →
P31754	—	0.930	P31754 →
UMPS	Uridine 5'-monophosphate synthase	0.929	landscape →
Q6GM82	—	0.929	Q6GM82 →
Q9W7M6	—	0.929	Q9W7M6 →